

## PACT – Patient New Clinical Trial and Research

---

Trial title	A participant- and investigator-blinded, randomized, placebo-controlled, multicentre, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
Trial synopsis	The purpose of this study is to look at how well the study treatment (LTP001) works and if it is safe and effective in participants with IPF. LTP001 is an oral medication taken every morning for the duration of the study
Investigational medicinal product	LTP001 vs placebo
Disease target	Idiopathic pulmonary fibrosis (IPF)
Sponsor	Novartis
Duration	42 day screening period + 26 weeks + 30 days follow up
Trial Status	Recruiting
Lead site(s) in Australia	<ul style="list-style-type: none"> <li>• <b>Lead private</b> TrialsWest (WA)</li> <li>• <b>Lead public</b> Westmead Hospital (NSW)</li> </ul>
Lead site(s) in New Zealand	N/A
Additional sites	<ul style="list-style-type: none"> <li>• Royal Prince Alfred Hospital (NSW)</li> <li>• Lung Research Queensland (QLD)</li> <li>• Austin Hospital (VIC)</li> </ul>
Contact	pactcoordinator@cre-pf.org.au